The battle in L.A. is not over yet, but two City Council committees have rejected draconian and bad advice from City Attorney Carmen Trutanich, the Los Angeles Times reports.
Last week’s announcement from the American Medical Association -- calling for a federal review of marijuana's legal status -- has been well received in the media, reaching the pages of The Washington Post, LA Times, and other publications. One group that hasn’t got the message is the Drug Enforcement Administration. This is no surprise, as the DEA has been ignoring recommendations to research marijuana’s medical benefits for decades.
But this example is particularly egregious. On the DEA Web page “Exposing the Myth of Smoked Medical Marijuana,” the agency writes, “the American Medical Association recommends that marijuana remain a Schedule I controlled substance.” That statement directly contradicts the new policy that the AMA issued last week.
There’s a fantastic article in today’s Los Angeles Times about the successful regulation of medical marijuana dispensaries in West Hollywood, where city leaders, neighbors and even school officials have learned to embrace the shops and their patients as part of the greater community:
In West Hollywood, city officials say, it's been more than two years since a resident has complained about a dispensary. Neighborhood watch leaders say their streets are safer because the dispensary guards are required to walk nearby blocks. School officials welcome dispensaries as neighbors. And the L.A. County Sheriff's Department, which patrols the city, says there have been no recent crimes at dispensaries and no calls from agitated neighbors.
As the article goes on to explain, this positive model provides a stark contrast to cities such as Los Angeles and San Diego that do not have regulations, and consequently have witnessed more tension between community members and existing dispensaries.
In case anyone needs proof of the mass media’s tendency to repeat government pronouncements without bothering to check their accuracy, here’s a small but telling example:
Inexplicably, when the U.S. Department of Justice issued a memo last month explaining that it would generally refrain from prosecuting medical marijuana activities that are clearly legal under state law, it mistakenly indicated that there are 14 medical marijuana states. DOJ’s goof was to include Maryland, where medical marijuana is not actually legal, but where state law provides for reduced penalties to patients who successfully present a medical-necessity defense.
DOJ’s goof has now traveled though most of the known universe, repeated by credulous news media. The Associated Press, after talking to MPP, at least included an explanatory note about the discrepancy, but others just repeated the mistake with no explanation, including Katie Couric of CBS, the Washington Post, Voice of America, the Guardian of London, and even the editorial page of the New York Times.
C’mon, guys, tell me that fact-checking isn’t entirely dead. Kudos to those media outlets that got it right, including CNN.
In its official response to the AMA’s recent call for a review of marijuana’s status as a Schedule I drug (barring any medical use) under federal law, the White House Office of National Drug Control Policy stated that it would defer to "the FDA's judgment that the raw marijuana plant cannot meet the standards for identity, strength, quality, purity, packaging and labeling required of medicine."
While we’re not used to factual accuracy from ONDCP, in this case they’re wrong not once, but twice.
First, there is absolutely no reason that plant medicines can’t be standardized and controlled for purity and potency. Indeed, the Netherlands has been doing just that for years, with medical marijuana distributed in Dutch pharmacies that is “of pharmaceutical quality and complies with the strictest requirements,” according to the Dutch government.
Second, the FDA has never said that a natural plant product can’t be a medicine. Indeed the agency has a lengthy “Guidance for Industry: Botanical Drug Products,” specifically designed to aid developers of plant medicines. The document not only doesn’t rule out plants as medicines, it even states, “In the initial stage of clinical studies of a botanical drug, it is generally not necessary to identify the active constituents or other biological markers or to have a chemical identification and assay for a particular constituent or marker.” Given that the active components of marijuana are already well-known and extensively researched, marijuana is well ahead of where the FDA says plant products need to be to start the process of seeking FDA licensing.
Yes, the FDA did put out a press release in 2006 saying that “smoked marijuana” had not been shown to be a safe and effective medicine. That statement was utterly unscientific, as we pointed out at the time, but it was absolutely not a declaration that the plant could never be a medicine.
The resignations keep piling on in Britain, weeks after that nation’s chief drug adviser, Prof. David Nutt, was fired for publicly criticizing several UK government drug policies, including a recent decision to strengthen marijuana penalties.
Today, three more members of the Advisory Council on the Misuse of Drugs were reported to have resigned in protest after they were unhappy with explanations offered by Home Secretary Alan Johnson, the man who demanded Nutt’s resignation. The resignations of Simon Campbell, Dr. Ian Ragan and John Marsden now bring to five the number of people on the once 31-member board who have left in protest since this saga began.
MPP Director of Government Relations Aaron Houston appears on Fox Freedom Watch to talk about the advances in marijuana policy and the failure of the drug war with Judge Andrew Napolitano. 11/09/2009
Big news: The American Medical Association adopted a new policy position today calling for the review of marijuana’s status as a Schedule I drug.
The revised policy "urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods.” While it goes on to explain that the AMA is not stating support for state medical marijuana laws, the new policy does fall in line with what is quickly becoming a universal understanding in American medicine: Marijuana has undeniable medical uses and federal law should reflect that reality.
The new policy marks a historic shift from the AMA’s previous position, which recommended that “marijuana be retained in Schedule I,” grouping marijuana with drugs such as heroin, LSD, and PCP that are deemed to have no accepted medical uses.
The AMA’s previous position was often cited by medical marijuana opponents as evidence that the drug’s medical efficacy was in question. This new policy will go a long way to convincing politicians and policy makers that the compassionate use of medical marijuana should not be blocked by outdated marijuana laws.
There has long been reason to think that marijuana may be helpful to some patients with bipolar disorder, as certain cannabinoids have been shown in lab and animal studies to have effects that ought to be beneficial. Now, a new study from the University of Oslo finds that marijuana use is associated with better neurocognitive functioning in bipolar patients. In various tests of memory, learning, etc., bipolar patients who used marijuana did better than those who didn’t use it – the exact opposite of what the researchers found in patients with schizophrenia, a condition marijuana can sometimes worsen. “The findings,” the scientists write, “suggest that cannabis use may be related to improved neurocognition in bipolar disorder.”
That alcohol causes cancer isn’t really news, but how it does so hasn’t been fully understood. A new study, published in the journal Alcoholism: Clinical and Experimental Research, adds an important new piece of information. Alcohol, it turns out, stimulates a type of cell transformation that turns cancer cells more aggressive and thus more likely to spread throughout the body.
As we’ve noted before, research shows that cannabinoids (marijuana’s unique, active components) interfere with tumor growth and may actually prevent cancer.